Učitavanje...
A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome
Chronic lymphocytic leukemia (CLL) is a progressive disease with an indolent course, and tumor lysis syndrome (TLS) is rarely seen in CLL. Ibrutinib is a novel bruton kinase (BTK) inhibitor increasingly used in CLL treatment. Ibrutinib has significant side effects such as atrial fibrillation, bleedi...
Spremljeno u:
| Izdano u: | Medeni Med J |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Istanbul Medeniyet University
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8226401/ https://ncbi.nlm.nih.gov/pubmed/34239769 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5222/MMJ.2021.56424 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|